SATB1 and pancreatic adenocarcinoma: The role of SATB1 remains controversial and appears to be specific to the type of cancer, in particular, high levels of SATB1 expression are associated with poor prognosis in colorectal cancer [27], loss of SATB1 – with poor prognosis in lung squamous cell carcinoma [28], expression of SATB1 was an independent predictor of a significantly shorter recurrence-free survival and OS in pancreatobiliary type, but not in intestinal type adenocarcinomas of pancreas; moreover, SATB1 expression predicted an improved response to adjuvant chemotherapy in both tumor types [29].